有毛細胞白血病市場：規模 - 治療タイプ別、治療法別、製品タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、地域別見通し、競合戦略、2033年までのセグメント別予測

世界の有毛細胞白血病の市場規模は、今後4.89％のCAGRで拡大し、2033年までに1億米ドルに達すると予測されています。

当レポートでは、世界の有毛細胞白血病市場について調査し、市場の概要とともに、治療タイプ別、治療法別、製品タイプ別、薬剤クラス別、投与経路別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因、抑制要因、機会、課題の分析
• COVID-19による世界の有毛細胞白血病市場への影響

第5章 市場変数と見通し

• SWOT分析
• PESTEL分析
• ポーターのファイブフォース
• ヒートマップ分析

第6章 競合情勢

第7章 世界の有毛細胞白血病市場、治療タイプ別（100万米ドル）

• 世界の有毛細胞白血病市場価値シェアと予測、治療タイプ別、2023年～2033年
• 投薬治療
• 外科手術

第8章 世界の有毛細胞白血病市場、治療法別（100万米ドル）

• 世界の有毛細胞白血病市場価値シェアと予測、治療法別、2023年～2033年
• 化学療法
• 免疫療法
• 標的療法

第9章 世界の有毛細胞白血病市場、製品タイプ別（100万米ドル）

• 世界の有毛細胞白血病市場価値シェアと予測、製品タイプ別、2023年～2033年
• カプセル
• 非経口薬
• タブレット
• その他

第10章 世界の有毛細胞白血病市場、薬剤クラス別（100万米ドル）

• 世界の有毛細胞白血病市場価値シェアと予測、薬剤クラス別、2023年～2033年
• ベルズティファン
• ベバシズマブ
• カルムスチン
• エベロリムス
• ロムスチン
• テモゾロミド
• その他

第11章 世界の有毛細胞白血病市場、投与経路別（100万米ドル）

• 世界の有毛細胞白血病市場価値シェアと予測、投与経路別、2023年～2033年
• 経口
• 非経口
• その他

第12章 世界の有毛細胞白血病市場、エンドユーザー別（100万米ドル）

• 世界の有毛細胞白血病市場価値シェアと予測、エンドユーザー別、2023年～2033年
• 在宅ケア
• 病院
• 専門クリニック
• その他

第13章 世界の有毛細胞白血病市場の予測、2019年～2033年（100万米ドル）

第14章 世界の有毛細胞白血病市場、治療タイプ別、2019年～2033年（100万米ドル）

第15章 世界の有毛細胞白血病市場、治療法別、2019年～2033年（100万米ドル）

第16章 世界の有毛細胞白血病市場、製品タイプ別、2019年～2033年（100万米ドル）

第17章 世界の有毛細胞白血病市場、薬剤クラス別、2019年～2033年（100万米ドル）

第18章 世界の有毛細胞白血病市場、投与経路別、2019年～2033年（100万米ドル）

第19章 世界の有毛細胞白血病市場、エンドユーザー別、2019年～2033年（100万米ドル）

第20章 世界の有毛細胞白血病市場、地域別、2019年～2033年（100万米ドル）

• 世界の有毛細胞白血病市場規模と地域別市場シェア（2019年～2026年）
• 世界の有毛細胞白血病市場規模と地域別市場シェア（2027年～2033年）
• アジア太平洋
• 欧州
• 中東・アフリカ
• 北米
• ラテンアメリカ

第21章 企業プロファイル

• AbbVie Inc
• Amgen Inc
• Astellas Pharma Inc
• Astex Therapeutics
• AstraZeneca
• Bayer AG
• Biogenomics Limited
• Bristol Myers Squibb Company
• Celgene Corporation
• Daiichi Sankyo Company Limited
• Dr. Reddy's Laboratories Ltd
• Eli Lilly and Company
• Emcure Pharmaceuticals
• Fresenius SE and Co. KGaA
• GlaxoSmithKline plc
• Hoffmann-La Roche
• Janssen Global Services
• Johnson & Johnson Services, Inc
• Merck & Co., Inc
• Novartis AG
• Pfizer Inc.
• Sumitomo Dainippon Pharma Co.
• Takeda Pharmaceutical Company Limited
• その他

第22章 略語のリスト

第23章 参照リンク

第24章 結論

第25章 調査範囲

Hairy Cell Leukemia Market Overview

According to SPER market research, 'Hairy Cell Leukemia Market Size- By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Hairy Cell Leukemia Market is predicted to reach USD 0.10 billion by 2033 with a CAGR of 4.89%.

Hairy cell leukaemia is a rare type of cancer, in which the bone marrow causes lymphocytes to develop out of control. The name "hairy cell leukaemia" refers to a characteristic of the disease's morphology. In hairy cell leukaemia, the extra B cells grow aberrant extensions and have a hairy appearance. The quantity of healthy white blood cells, red blood cells, and platelets in the body decrease noticeably as the number of leukaemia cells increases. Usually, the illness takes time to develop without any noticeable symptoms.

Healthcare services were affected as a result of the COVID-19 pandemic, reducing access to basic care, including diagnosis and treatment. Delays in the clinical trials for the new treatments have an impact on therapy developments. Disruptions in the supply chain made it difficult to manage treatment plans and obtain the necessary drugs. There were fewer in-person visits and monitoring sessions, which increased reliance on online consultations. Challenges with affordability and reimbursement arose as a result of financial issues.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2033

Base year considered 2022

Forecast period 2023-2033

Segments covered By Treatment Type, By Therapy Type, By Product Type, By Drug Class, By Route of Administration, By End User

Regions covered Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America

Companies Covered AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Astex Therapeutics, AstraZeneca, Bayer AG, Biogenomics Limited, Bristol Myers Squibb Company, Fresenius SE and Co. KGaA, GlaxoSmithKline plc, Hoffmann-La Roche, Janssen Global Services,

Hairy Cell Leukemia Market Key Segments Covered

By Therapy Type: Based on the Therapy Type, Global Hairy Cell Leukemia Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy.

By Product Type: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Capsules, Parenterals, Tablets, Others.

By End User: Based on the Product Type, Global Hairy Cell Leukemia Market is segmented as; Homecare, Hospitals, Specialty Clinics, Others.

By Region: This research also includes data for Asia-Pacific, Europe, the Middle East and Africa, North America, and Latin America.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1. Research data source
  • 2.1.1. Secondary Data
  • 2.1.2. Primary Data
  • 2.1.3. SPER's internal database
  • 2.1.4. Premium insight from KOL's
• 2.2. Market size estimation
  • 2.2.1. Top-down and Bottom-up approach
• 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
  • 4.1.4. Challenges
• 4.2. COVID-19 Impacts of the Global Hairy Cell Leukemia Market

5. Market variable and outlook

• 5.1. SWOT Analysis
  • 5.1.1. Strengths
  • 5.1.2. Weaknesses
  • 5.1.3. Opportunities
  • 5.1.4. Threats
• 5.2. PESTEL Analysis
  • 5.2.1. Political Landscape
  • 5.2.2. Economic Landscape
  • 5.2.3. Social Landscape
  • 5.2.4. Technological Landscape
  • 5.2.5. Environmental Landscape
  • 5.2.6. Legal Landscape
• 5.3. PORTER's Five Forces
  • 5.3.1. Bargaining power of suppliers
  • 5.3.2. Bargaining power of buyers
  • 5.3.3. Threat of Substitute
  • 5.3.4. Threat of new entrant
  • 5.3.5. Competitive rivalry
• 5.4. Heat Map Analysis

6. Competitive Landscape

• 6.1. Global Hairy Cell Leukemia Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Hairy Cell Leukemia Market

7. Global Hairy Cell Leukemia Market, By Treatment Type (USD Million)

• 7.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Treatment Type, 2023-2033
• 7.2. Medication
• 7.3. Surgery

8. Global Hairy Cell Leukemia Market, By Therapy Type (USD Million)

• 8.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Therapy Type, 2023-2033
• 8.2. Chemotherapy
• 8.3. Immunotherapy
• 8.4. Targeted Therapy

9. Global Hairy Cell Leukemia Market, By Product Type (USD Million)

• 9.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Product Type, 2023-2033
• 9.2. Capsules
• 9.3. Parenterals
• 9.4. Tablets
• 9.5. Others

10. Global Hairy Cell Leukemia Market, By Drug Class (USD Million)

• 10.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Drug Class, 2023-2033
• 10.2. Belzutifan
• 10.3. Bevacizumab
• 10.4. Carmustine
• 10.5. Everolimus
• 10.6. Lomustine
• 10.7. Temozolomide
• 10.8. Others

11. Global Hairy Cell Leukemia Market, By Route of Administration (USD Million)

• 11.1. Global Hairy Cell Leukemia Market Value Share and Forecast, By Route of Administration, 2023-2033
• 11.2. Oral
• 11.3. Parenteral
• 11.4. Others

12. Global Hairy Cell Leukemia Market, By End User (USD Million)

• 12.1. Global Hairy Cell Leukemia Market Value Share and Forecast, End User, 2023-2033
• 12.2. Homecare
• 12.3. Hospitals
• 12.4. Specialty Clinics
• 12.5. Others

13. Global Hairy Cell Leukemia Market Forecast, 2019-2033 (USD Million)

• 13.1. Global Hairy Cell Leukemia Market Size and Market Share

14. Global Hairy Cell Leukemia Market, By Treatment Type, 2019-2033 (USD Million)

• 14.1. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2019-2026)
• 14.2. Global Hairy Cell Leukemia Market Size and Market Share By Treatment Type (2027-2033)

15. Global Hairy Cell Leukemia Market, By Therapy Type, 2019-2033 (USD Million)

• 15.1. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2019-2026)
• 15.2. Global Hairy Cell Leukemia Market Size and Market Share By Therapy Type (2027-2033)

16. Global Hairy Cell Leukemia Market, By Product Type, 2019-2033 (USD Million)

• 16.1. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2019-2026)
• 16.2. Global Hairy Cell Leukemia Market Size and Market Share By Product Type (2027-2033)

17. Global Hairy Cell Leukemia Market, By Drug Class, 2019-2033 (USD Million)

• 17.1. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2019-2026)
• 17.2. Global Hairy Cell Leukemia Market Size and Market Share By Drug Class (2027-2033)

18. Global Hairy Cell Leukemia Market, By Route of Administration, 2019-2033 (USD Million)

• 18.1. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2019-2026)
• 18.2. Global Hairy Cell Leukemia Market Size and Market Share By Route of Administration (2027-2033)

19. Global Hairy Cell Leukemia Market, By End User, 2019-2033 (USD Million)

• 19.1. Global Hairy Cell Leukemia Market Size and Market Share By End User (2019-2026)
• 19.2. Global Hairy Cell Leukemia Market Size and Market Share By End User (2027-2033)

20. Global Hairy Cell Leukemia Market, By Region, 2019-2033 (USD Million)

• 20.1. Global Hairy Cell Leukemia Market Size and Market Share By Region (2019-2026)
• 20.2. Global Hairy Cell Leukemia Market Size and Market Share By Region (2027-2033)
• 20.3. Asia-Pacific
  • 20.3.1. Australia
  • 20.3.2. China
  • 20.3.3. India
  • 20.3.4. Japan
  • 20.3.5. South Korea
  • 20.3.6. Rest of Asia-Pacific
• 20.4. Europe
  • 20.4.1. France
  • 20.4.2. Germany
  • 20.4.3. Italy
  • 20.4.4. Spain
  • 20.4.5. United Kingdom
  • 20.4.6. Rest of Europe
• 20.5. Middle East and Africa
  • 20.5.1. Kingdom of Saudi Arabia
  • 20.5.2. United Arab Emirates
  • 20.5.3. Rest of Middle East & Africa
• 20.6. North America
  • 20.6.1. Canada
  • 20.6.2. Mexico
  • 20.6.3. United States
• 20.7. Latin America
  • 20.7.1. Argentina
  • 20.7.2. Brazil
  • 20.7.3. Rest of Latin America

21. Company Profile

• 21.1. AbbVie Inc,
  • 21.1.1. Company details
  • 21.1.2. Financial outlook
  • 21.1.3. Product summary
  • 21.1.4. Recent developments
• 21.2. Amgen Inc
  • 21.2.1. Company details
  • 21.2.2. Financial outlook
  • 21.2.3. Product summary
  • 21.2.4. Recent developments
• 21.3. Astellas Pharma Inc
  • 21.3.1. Company details
  • 21.3.2. Financial outlook
  • 21.3.3. Product summary
  • 21.3.4. Recent developments
• 21.4. Astex Therapeutics
  • 21.4.1. Company details
  • 21.4.2. Financial outlook
  • 21.4.3. Product summary
  • 21.4.4. Recent developments
• 21.5. AstraZeneca
  • 21.5.1. Company details
  • 21.5.2. Financial outlook
  • 21.5.3. Product summary
  • 21.5.4. Recent developments
• 21.6. Bayer AG
  • 21.6.1. Company details
  • 21.6.2. Financial outlook
  • 21.6.3. Product summary
  • 21.6.4. Recent developments
• 21.7. Biogenomics Limited
  • 21.7.1. Company details
  • 21.7.2. Financial outlook
  • 21.7.3. Product summary
  • 21.7.4. Recent developments
• 21.8. Bristol Myers Squibb Company
  • 21.8.1. Company details
  • 21.8.2. Financial outlook
  • 21.8.3. Product summary
  • 21.8.4. Recent developments
• 21.9. Celgene Corporation
  • 21.9.1. Company details
  • 21.9.2. Financial outlook
  • 21.9.3. Product summary
  • 21.9.4. Recent developments
• 21.10. Daiichi Sankyo Company Limited
  • 21.10.1. Company details
  • 21.10.2. Financial outlook
  • 21.10.3. Product summary
  • 21.10.4. Recent developments
• 21.11. Dr. Reddy's Laboratories Ltd
  • 21.11.1. Company details
  • 21.11.2. Financial outlook
  • 21.11.3. Product summary
  • 21.11.4. Recent developments
• 21.12. Eli Lilly and Company
  • 21.12.1. Company details
  • 21.12.2. Financial outlook
  • 21.12.3. Product summary
  • 21.12.4. Recent developments
• 21.13. Emcure Pharmaceuticals
  • 21.13.1. Company details
  • 21.13.2. Financial outlook
  • 21.13.3. Product summary
  • 21.13.4. Recent developments
• 21.14. Fresenius SE and Co. KGaA
  • 21.14.1. Company details
  • 21.14.2. Financial outlook
  • 21.14.3. Product summary
  • 21.14.4. Recent developments
• 21.15. GlaxoSmithKline plc
  • 21.15.1. Company details
  • 21.15.2. Financial outlook
  • 21.15.3. Product summary
  • 21.15.4. Recent developments
• 21.16. Hoffmann-La Roche
  • 21.16.1. Company details
  • 21.16.2. Financial outlook
  • 21.16.3. Product summary
  • 21.16.4. Recent developments
• 21.17. Janssen Global Services
  • 21.17.1. Company details
  • 21.17.2. Financial outlook
  • 21.17.3. Product summary
  • 21.17.4. Recent developments
• 21.18. Johnson & Johnson Services, Inc.
  • 21.18.1. Company details
  • 21.18.2. Financial outlook
  • 21.18.3. Product summary
  • 21.18.4. Recent developments
• 21.19. Merck & Co., Inc
  • 21.19.1. Company details
  • 21.19.2. Financial outlook
  • 21.19.3. Product summary
  • 21.19.4. Recent developments
• 21.20. Novartis AG
  • 21.20.1. Company details
  • 21.20.2. Financial outlook
  • 21.20.3. Product summary
  • 21.20.4. Recent developments
• 21.21. Pfizer Inc.
  • 21.21.1. Company details
  • 21.21.2. Financial outlook
  • 21.21.3. Product summary
  • 21.21.4. Recent developments
• 21.22. Sumitomo Dainippon Pharma Co.,
  • 21.22.1. Company details
  • 21.22.2. Financial outlook
  • 21.22.3. Product summary
  • 21.22.4. Recent developments
• 21.23. Takeda Pharmaceutical Company Limited
  • 21.23.1. Company details
  • 21.23.2. Financial outlook
  • 21.23.3. Product summary
  • 21.23.4. Recent developments
• 21.24. Others

22. List of Abbreviations

23. Reference Links

24. Conclusion

25. Research Scope